🚨The future of #ThoracicOncology is in great hands!

My co-chair colleague Dr Christian Rolfo, myself, great faculty mentors, & #IASLC staff are honored to kick off the:

“2024 global IASLC #Academy .”

Welcome to an outstanding group of #EarlyCareer #Physicians & #Researchers .

Please take a minute to fill out the survey on #BiomarkerTesting . This will help understand the gaps, and define our efforts moving forward globally, to personalize therapy in #NSCLC IASLC Karen Kelly Matthew Smeltzer

iaslc.org/research-educa…

Beautiful talk by superstar first year fellow Sarah Waliany, MD, MS sharing findings from a retrospective study of carbo/pem + ALK TKI vs carbo/pem alone after progression of ALK TKI monotherapy, which results in clinically meaningful CNS control. 🔥🙌 #TTLC24 IASLC MGH Women in Oncology MGH Thoracic Oncology

1. Pumped to share that our article “Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study” is now out in JTO!
jto.org/article/S1556-…

You don’t have to be in the same “area of research”, department or even institution (on occasion) to serve as a sponsor or advocate for #WomeninMedicine and other URiM. Leaders should reflect on this towards the end of the year and consider doing more of it! Goes a LONG way!

Repotrectinib is FDA approved for ROS1+ lung cancers in the TKI naive and pretreated settings. Many thanks to the patients, advocates, and study teams around the world who made this possible. onclive.com/view/fda-appro…

We are honored to have @drjaimelaurel of Harvard Medical School as our morning keynote speaker at this year’s Midwest Lung Cancer Summit. Dr. Schneider was the recipient of the 2022 Peg’s Fight For Life Research Award. Register today!
#lungcancer #lungcancer awareness

Dynamic🌟duo Kerry Reynolds Han Zhu discuss CV IRAEs & biomarkers, reviewing🔑studies on ICI myocarditis! #JACCCardioOnc Pulse

🔷TnT🆚TnI🆚CK as prognosticators of MACE
🔷Titrating immunosuppression w/ TnT
🔷Unmet needs eg. refractory cases
🔷ATRIUM trial
tinyurl.com/46upuj9u

Register now for the IASLC #NACLC23 meeting, December 1-3 in Chicago, IL! Abstract submission and registration are now open for this engaging meeting with plenty of educational and networking opportunities. Hope to see you there! #LCSM

iaslc.org/2023-north-ame…

The Linnea Olson Award for Patient Advocacy was established in '22 to honor the life & legacy of Linnea Olson. At Medidata NEXT NYC 2023, we will honor a patient advocate driving change in clinical research. Nominate an advocate today! #BCSM #LCSM
docs.google.com/forms/d/e/1FAI…

Dr JessicaJLinMD’s message pinned to the PHLHopeFence captured the hearts and minds of our ALK+ #cancer community:

Cure ALK+ #Lungcancer

We couldn’t say it better ourselves.

Thanks Dr Lin for being such a supportive member of our community.

#ALKSummit2023 #StrongerTogether

Thank you for having us ALK Positive at the #ALKSummit2023 . What a powerful, inspiring event. Will be bringing back the energy, vision and hope back to Boston Mass General Cancer Center.
We are, indeed, #StrongerTogether

We are so grateful & fortunate to have Ivy Elkins joining us as the patient/research advocate speaker GRACE, sharing her insights from the advocacy journey with the community. Thank you Ivy Elkins for your powerful, impactful talk, and for all your contributions🙏 #LCSM

Dr. Joshua Sabari, MD now on stage: 'KRAS mutations are not all the same - alleles and comutations matter'
Targeted Therapies Forum 2023 GRACE

Key message from Stephen V Liu, MD during the Targeted Therapies Forum 2023 GRACE: 'Identifying rare fusions is critical for proper care! NGS is the best approach.'

Targeted therapy expert Dr. Misako Nagasaka discussing the current treatment paradigm and recent advances in ALK/ROS1 NSCLC at the Targeted Therapies Forum GRACE